Upcoming AACR 2026 event announcement sees Nuvalent stock down 1.43%

Traders Union
All News
Companies
Nuvalent slides 1.43% today

Highlights

NUVL remains under short- and medium-term selling pressure, but the long-term uptrend is intact as it consolidates near $96.66.
Momentum indicators are broadly bearish, signaling weak buyer conviction and an elevated risk of further downside in the near term.
The expected price range for the coming week is $93.50 to $100.50, with key support at $91.96 and resistance at $100.75.

NUVL is trading at $96.66, which is below the SMA-20 ($98.87) and SMA-50 ($101.97) but above the SMA-200 ($91.96), indicating continued short- and medium-term selling pressure, with a longer-term uptrend still intact. The Ichimoku Kijun level on D1 stands at $100.75, acting as immediate resistance; near-term support is at the SMA-200 ($91.96), and key support is at SMA-100 ($102.32); near-term resistance is the SMA-20 ($98.87), with the Ichimoku Kijun ($100.75) as the key resistance.

Momentum is negative, as both the MACD and ADX on D1 signal a strong sell and a lack of clear directional strength. RSI, Stoch RSI, and CCI are all in "sell" territory, with CCI nearing oversold and Stoch RSI at mid-range, while BBP on D1 shows a pronounced overbought reading near recent highs, suggesting buyers were dominating but momentum has faded. The Awesome Oscillator remains neutral, not confirming a directional move. In today's session, NUVL is down 1.43% after opening nearly unchanged. Over the past week, NUVL is trading at $96.66, up from a previous weekly close of $94.77, marking a 1.99% gain. The price sits in the middle of the weekly range, with volatility amplitude at 7.20%. Overall, the week is characterized by consolidation and modest recovery from the lows, even as short-term oscillators and momentum remain broadly bearish.

Looking ahead, the expected price range for the coming week is $93.50 to $100.50, in line with recent weekly volatility and keeping within 7–8% of the current price. Given the strong buy signals from MACD-W1 and MA-50-W1 but a sell from RSI-W1 and a neutral ADX-W1, the probability of a price increase is moderate, at about 50%, making a decrease equally likely. The baseline scenario expects NUVL to remain in a sideways corridor, tracking between recent support and resistance. If bullish momentum returns and the price breaks above $98.87–$100.75 resistance, a move toward previous highs could follow. Conversely, a decisive break below $91.96 support would expose the stock to further downside. The forecast range remains well above the 52-week low ($55.54), but still 15% below the 52-week high ($113.02), reflecting ongoing consolidation after last year’s strong gains.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Nuvalent intended to share new clinical and preclinical data for its ROS1-positive NSCLC program at the AACR 2026 Annual Meeting. The current developments provide further insight into the company's progress, with the key risk to monitor being the impact of upcoming trial results on investor sentiment.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.